Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

Completed

Conditions studied: Meningitis, Meningococcal Infection

In brief

This is a passive-surveillance study that will accrue subjects for surveillance. For each accrued subject, surveillance for outcomes will continue for six months following the first dose. If a second dose is given within that time, then surveillance will be continued for six months following the second dose. Observational Objective: * To describe and characterize adverse events occurring after vaccination with Menactra vaccine.

Key facts

Study ID

NCT01689155

Run by

Sanofi Pasteur, a Sanofi Company

People needed

116

Starts

2011-06-01

Expected to finish

2016-04-01

Last updated by the study team

2016-11-11

Who can join

Age: 1 and older, up to 2. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 9 to 23 months at the time of receipt of the first dose of Menactra vaccine during the study period.

Where it is running

• Study site — Oakland, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.